

# **Cancer Supportive Care Drugs Market Size, Trends, Analysis, and Outlook By Therapeutic Class (G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Anti-emetics, Bisphosphonates, Opioids, NSAIDs and Others), by Region, Country, Segment, and Companies, 2024-2030**

<https://marketpublishers.com/r/C224857D0C14EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: C224857D0C14EN

## **Abstracts**

The global Cancer Supportive Care Drugs market size is poised to register 3.6% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Cancer Supportive Care Drugs market across By Therapeutic Class (G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Anti-emetics, Bisphosphonates, Opioids, NSAIDs and Others).

The Cancer Supportive Care Drugs Market is experiencing notable growth and therapeutic innovation in 2024 and beyond, driven by advancements in supportive oncology, symptom management, and patient-centered care approaches aimed at addressing the complex, multidimensional needs of cancer patients undergoing active treatment, survivorship, or end-of-life care, as well as for their caregivers and families navigating the physical, emotional, and psychosocial challenges of cancer-related symptoms, treatment side effects, and supportive care needs throughout the cancer care continuum. Cancer supportive care drugs encompass a diverse range of pharmaceutical agents, including antiemetics, analgesics, hematopoietic growth factors, psychotropic medications, and palliative care drugs, designed to alleviate cancer-related symptoms, manage treatment toxicities, and improve quality of life for cancer patients by reducing pain, nausea, fatigue, anemia, cachexia, and other treatment-related complications while optimizing symptom control, functional status, and treatment

adherence in clinical practice. Key trends include the development of targeted supportive care interventions, precision symptom management strategies, and personalized treatment approaches that tailor supportive care interventions to individual patient needs, treatment regimens, and symptom clusters, as well as the integration of multidisciplinary supportive care teams, symptom assessment tools, and survivorship care plans into cancer care pathways to optimize supportive care delivery, enhance patient-provider communication, and promote shared decision-making processes that prioritize patients' treatment preferences, symptom management goals, and quality of life considerations in oncology practice. Additionally, there is a growing emphasis on survivorship care models, survivorship care planning, and survivorship care coordination services that address the long-term physical, psychosocial, and socioeconomic needs of cancer survivors and their families after completing active treatment, as well as a growing focus on caregiver support programs, caregiver respite services, and caregiver education initiatives that provide practical assistance, emotional support, and coping strategies for family caregivers and informal caregivers supporting cancer patients throughout their cancer journey. Moreover, collaborative partnerships between oncology healthcare providers, supportive care specialists, and patient advocacy organizations are essential for advancing supportive care research, implementing best practices, and improving symptom management and quality of life outcomes for cancer patients and their families worldwide.

## Cancer Supportive Care Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Cancer Supportive Care Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Cancer Supportive Care Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Cancer Supportive Care Drugs industry.

## Key market trends defining the global Cancer Supportive Care Drugs demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Cancer Supportive Care Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Cancer Supportive Care Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Cancer Supportive Care Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Cancer Supportive Care Drugs industry

Leading Cancer Supportive Care Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Cancer Supportive Care Drugs companies.

### Cancer Supportive Care Drugs Market Study- Strategic Analysis Review

The Cancer Supportive Care Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and

economic changes.

## Cancer Supportive Care Drugs Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Cancer Supportive Care Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

## Cancer Supportive Care Drugs Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

## North America Cancer Supportive Care Drugs Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Cancer Supportive Care Drugs market segments. Similarly, Strong end-user demand is encouraging Canadian Cancer Supportive Care Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Cancer Supportive Care Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

## Europe Cancer Supportive Care Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Cancer Supportive Care Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period,

driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Cancer Supportive Care Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

**Asia Pacific Cancer Supportive Care Drugs Market Size Outlook-** an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Cancer Supportive Care Drugs in Asia Pacific. In particular, China, India, and South East Asian Cancer Supportive Care Drugs markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

**Latin America Cancer Supportive Care Drugs Market Size Outlook-** Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

**Middle East and Africa Cancer Supportive Care Drugs Market Size Outlook-** continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Cancer Supportive Care Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Cancer Supportive Care Drugs.

## Cancer Supportive Care Drugs Market Company Profiles

The global Cancer Supportive Care Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Acacia Pharma Group Plc, Amgen Inc, Celldex Therapeutics, F. Hoffmann-La Roche AG, Helsinn Healthcare, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co. Inc, Novartis (Sandoz), Sanofi, Sun Pharmaceutical Industries Ltd

## Recent Cancer Supportive Care Drugs Market Developments

The global Cancer Supportive Care Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

## Cancer Supportive Care Drugs Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

## Case Scenarios- Low, Base, High

### Market Segmentation:

#### By Therapeutic Class

G-CSFs (Granulocyte-colony Stimulating Factors)

ESAs (Erythropoiesis Stimulating Agents)

Anti-emetics

Bisphosphonates

Opioids

NSAIDs and Others

### Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

### Companies

Acacia Pharma Group Plc

Amgen Inc

Celldex Therapeutics

F. Hoffmann-La Roche AG

Helsinn Healthcare

Heron Pharma

Ipsen Pharma

Johnson & Johnson

Merck & Co. Inc

Novartis (Sandoz)

Sanofi

Sun Pharmaceutical Industries Ltd

Formats Available: Excel, PDF, and PPT



## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Cancer Supportive Care Drugs Market Overview and Key Findings, 2024
- 1.2 Cancer Supportive Care Drugs Market Size and Growth Outlook, 2021- 2030
- 1.3 Cancer Supportive Care Drugs Market Growth Opportunities to 2030
- 1.4 Key Cancer Supportive Care Drugs Market Trends and Challenges
  - 1.4.1 Cancer Supportive Care Drugs Market Drivers and Trends
  - 1.4.2 Cancer Supportive Care Drugs Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Cancer Supportive Care Drugs Companies

### **2. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE OUTLOOK TO 2030**

- 2.1 Cancer Supportive Care Drugs Market Size Outlook, USD Million, 2021- 2030
- 2.2 Cancer Supportive Care Drugs Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### **3. CANCER SUPPORTIVE CARE DRUGS MARKET- STRATEGIC ANALYSIS REVIEW**

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### **4. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK**

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030  
By Therapeutic Class  
G-CSFs (Granulocyte-colony Stimulating Factors)

ESAs (Erythropoiesis Stimulating Agents)

Anti-emetics

Bisphosphonates

Opioids

NSAIDs and Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## **5. REGION-WISE MARKET OUTLOOK TO 2030**

5.1 Key Findings for Asia Pacific Cancer Supportive Care Drugs Market, 2025

5.2 Asia Pacific Cancer Supportive Care Drugs Market Size Outlook by Type, 2021-2030

5.3 Asia Pacific Cancer Supportive Care Drugs Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Cancer Supportive Care Drugs Market, 2025

5.5 Europe Cancer Supportive Care Drugs Market Size Outlook by Type, 2021- 2030

5.6 Europe Cancer Supportive Care Drugs Market Size Outlook by Application, 2021-2030

5.7 Key Findings for North America Cancer Supportive Care Drugs Market, 2025

5.8 North America Cancer Supportive Care Drugs Market Size Outlook by Type, 2021-2030

5.9 North America Cancer Supportive Care Drugs Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Cancer Supportive Care Drugs Market, 2025

5.11 South America Pacific Cancer Supportive Care Drugs Market Size Outlook by Type, 2021- 2030

5.12 South America Cancer Supportive Care Drugs Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Cancer Supportive Care Drugs Market, 2025

5.14 Middle East Africa Cancer Supportive Care Drugs Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Cancer Supportive Care Drugs Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Cancer Supportive Care Drugs Market Size Outlook and Revenue Growth

*Cancer Supportive Care Drugs Market Size, Trends, Analysis, and Outlook By Therapeutic Class (G-CSFs (Granuloc...*

## Forecasts

- 6.2 US Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Cancer Supportive Care Drugs Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Cancer Supportive Care Drugs Industry Drivers and

## Opportunities

6.39 Middle East Market Size Outlook and Revenue Growth Forecasts

6.40 Middle East Cancer Supportive Care Drugs Industry Drivers and Opportunities

6.41 Africa Market Size Outlook and Revenue Growth Forecasts

6.42 Africa Cancer Supportive Care Drugs Industry Drivers and Opportunities

## **7. CANCER SUPPORTIVE CARE DRUGS MARKET OUTLOOK ACROSS SCENARIOS**

7.1 Low Growth Case

7.2 Reference Growth Case

7.3 High Growth Case

## **8. CANCER SUPPORTIVE CARE DRUGS COMPANY PROFILES**

8.1 Profiles of Leading Cancer Supportive Care Drugs Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

Acacia Pharma Group Plc

Amgen Inc

Celldex Therapeutics

F. Hoffmann-La Roche AG

Helsinn Healthcare

Heron Pharma

Ipsen Pharma

Johnson & Johnson

Merck & Co. Inc

Novartis (Sandoz)

Sanofi

Sun Pharmaceutical Industries Ltd

## **9. APPENDIX**

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

## I would like to order

Product name: Cancer Supportive Care Drugs Market Size, Trends, Analysis, and Outlook By Therapeutic Class (G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Anti-emetics, Bisphosphonates, Opioids, NSAIDs and Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/C224857D0C14EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C224857D0C14EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970